AstraZeneca verdict from England: trials on children suspended

LAST MINUTE NEWS: Astrazeneca statement from the European Medicines Agency – Health News

last minute “data-mce-href =” “> Breaking news!

The European Medicines Agency (EMA), the European Union’s drug regulator, said the link between the Oxford / AstraZeneca vaccine and blood clots is possible.

EMA highlighted that the benefits of the vaccine still outweigh the risks. The EMA concluded that blood coagulation should be listed as the ‘very rare’ side effect of the AstraZeneca vaccine, while the EMA’s safety committee noted that unusual blood clots with low platelets should be listed as the very rare side effects of the AstraZeneca vaccine.


The European Medicines Agency (EMA) states that the Oxford / AstraZeneca vaccine should continue to be used in all age groups, while unusual blood clots with low platelets should be listed as a very rare side effect.

EMA highlighted that people who will be vaccinated should be informed of the possibility of very rare blood clots with low levels of blood platelets that may occur within 2 weeks after vaccination.

The European Medicines Agency said in a statement that the combination of blood clots and low blood platelets reported by people with the Oxford / AstraZeneca Covid-19 vaccine is very rare, and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.

EMA reported that the combination of blood clots and low platelets was caused by an immune response that sometimes caused a problem similar to that seen in patients treated with heparin (heparin-induced thrombocytopenia).

Details of the last minute development are soon on …

Leave a Reply

Your email address will not be published. Required fields are marked *